Technical Analysis for COCP - Cocrystal Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | 3.00% | |
Stochastic Reached Oversold | Weakness | 3.00% | |
Oversold Stochastic | Weakness | 3.00% | |
Crossed Above 20 DMA | Bullish | -5.88% | |
NR7 | Range Contraction | -1.64% | |
NR7-2 | Range Contraction | -1.64% | |
Narrow Range Bar | Range Contraction | -1.64% | |
Down 3 Days in a Row | Weakness | -1.64% |
Alert | Time |
---|---|
Possible Inside Day | about 6 hours ago |
Up 3% | about 10 hours ago |
Up 2% | about 10 hours ago |
Up 1% | about 10 hours ago |
Down 1% | about 11 hours ago |
Get a Trading Assistant
- Earnings date: 08/12/2024
Cocrystal Pharma, Inc. Description
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Influenza Coronavirus Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.285 |
52 Week Low | 1.325 |
Average Volume | 32,590 |
200-Day Moving Average | 1.78 |
50-Day Moving Average | 2.08 |
20-Day Moving Average | 2.50 |
10-Day Moving Average | 2.49 |
Average True Range | 0.22 |
RSI (14) | 51.46 |
ADX | 52.17 |
+DI | 27.11 |
-DI | 12.42 |
Chandelier Exit (Long, 3 ATRs) | 2.43 |
Chandelier Exit (Short, 3 ATRs) | 2.82 |
Upper Bollinger Bands | 2.78 |
Lower Bollinger Band | 2.22 |
Percent B (%b) | 0.33 |
BandWidth | 22.32 |
MACD Line | 0.09 |
MACD Signal Line | 0.14 |
MACD Histogram | -0.0477 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.58 | ||||
Resistance 3 (R3) | 2.56 | 2.49 | 2.55 | ||
Resistance 2 (R2) | 2.49 | 2.44 | 2.50 | 2.54 | |
Resistance 1 (R1) | 2.44 | 2.41 | 2.47 | 2.46 | 2.53 |
Pivot Point | 2.37 | 2.37 | 2.38 | 2.38 | 2.37 |
Support 1 (S1) | 2.32 | 2.32 | 2.35 | 2.34 | 2.27 |
Support 2 (S2) | 2.25 | 2.29 | 2.26 | 2.26 | |
Support 3 (S3) | 2.20 | 2.25 | 2.25 | ||
Support 4 (S4) | 2.22 |